Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 21INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Hyperglycemia 1Hereditary Sensory and Autonomic Neuropathies 1Diabetes Mellitus, Type 2 1Diabetes Mellitus 1Breast Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × dapagliflozin × Clear all
NCT07033585 2025-07-11

GD-T2D

Medicine Invention Design, Inc

Phase 2/3 Active not recruiting
600 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 2

NCT04899349 2024-10-09

EPIK-B4

Novartis

Phase 2 Terminated
2 enrolled 8 charts
Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡